Bioxyne secures major European expansion with $50 million German supply deal. The ASX-listed biotech company has signed an exclusive agreement with ADREXpharma, Germany's largest medicinal cannabis distributor, guaranteeing $25 million in minimum revenue during the first year. The contract includes automatic 12-month renewal, providing substantial revenue visibility. Germany represents Europe's largest medicinal cannabis market at approximately 200 tonnes annually, positioning Bioxyne strategically within this high-growth territory. The deal leverages Bioxyne's GMP-certified Australian cannabis products and builds on existing international expansion efforts across the UK, Latin America, and manufacturing partnerships with Aurora Cannabis. This agreement directly supports the company's commercial positioning and volume execution in a major European market.
Post from MarketNews_en
Log in to interact with content.